Robbins Farley’s Tandem Diabetes Care TNDM Stock Holding History

Robbins Farley’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	-$15K	–	179
2021 Q4	$15K	Buy	+100	New	+$13.5K	0.01%	83

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Robbins Farley's TNDM Position: Q1 2022 in Review

Robbins Farley sold out of Tandem Diabetes Care (TNDM) in Q1 2022, closing a stake of 100 shares — an estimated $15K sold.

Robbins Farley first reported a position in TNDM in Q4 2021 and held it in 1 quarter. The position peaked at $15K in Q4 2021. 379 funds tracked by Wall St. Rank hold TNDM as of Q1 2022.

Robbins Farley reported no remaining Tandem Diabetes Care position as of Q1 2022 after selling out during the quarter.
Robbins Farley sold 100 Tandem Diabetes Care shares in Q1 2022, an estimated $15K.
Robbins Farley first reported a position in Tandem Diabetes Care in Q4 2021 and held it in 1 quarter.
Robbins Farley's Tandem Diabetes Care position peaked at $15K in Q4 2021.
379 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2022.

Based on Robbins Farley's 13F filing for Q1 2022, filed 16 May 2022.